Kath. St. Paulus GmbH — Clinical Trial Site

31 Registered trials

12 Currently recruiting

Organisation

Kath. St. Paulus GmbH

Location

Dortmund, Germany

Identifier

ORG-100033644

Address

Johannesstrasse 9-17, Mitte, 44137, Germany

Departments

#2103: St.-Johannes-Hospital, Klinik fuer Innere Medizin I, Kardiologie
#3462:Klinik für Innere Medizin I
3462: Klinik für Innere Medizin I
Abteilung für Klinische Forschung Bereich Onkologische Studien
Allgemeine Innere Medizin
Clinic for Internal Medicine II
Department of Obstetrics/Gynecology
Hämatologie/Onkologie
Innere Medizin II
Internal Medicine II
Klinik für Gynäkologie und Geburtshilfe
Klinik für Hämatologie
Klinik für Innere Medizin I
Klinik für Innere Medizin II
Klinik für Innere Medizin II Onkozentrum
Klinische Forschung
Medizinische Klinik II
Medizinische Klinik II, Onkologie
N/A
NA
Onkologie
Practice
St. Johannes Hospital Dortmund
St.-Johannes Hospital, Klinik für Innere Medizin I

Clinical trials at this site (31)

Search interface

An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 Diffuse large B-cell lymphoma (DLBCL) 4 2025-09-30
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting

2023-509292-17-00 primary high-risk lobular breast cancer 4 2024-11-08
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
A clinical trial to learn more about the effects of DII235 in people with high levels of lipoprotein(a) Ended

2025-521912-21-00 Cardiovascular risk reduction in participants with elev 4 2026-01-26
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Ended

2022-500453-16-00 Multiple Myeloma 4 2023-10-30
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
To investigate PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated re-lapsed/refractory AML or MDS/AML pa… Halted

2024-514051-15-00 Adult patients with relapsed or refractory IDH1-mutated 7 2023-07-10
First Clinical Trial with activated regulatory T-cells in patients early after haematopoietic stem cell transplantation (HSCT) Ended

2024-516599-14-00 Leukaemia 7 2023-12-13
A study to test whether BI 765845 helps people who have had a heart attack Ended

2022-502788-39-00 acute myocardial infarction 4 2023-11-27